Abstract: Provided are compounds useful for treating of cancer and methods for treating of cancer, comprising administering to a subject in need thereof a compound described therein.

Abstract: Embodiments provided herein, provide for variant IgG Fc polypeptides, dimeric molecules, pharmaceutical compositions, and methods that can be used to target at cells to modulate the activity of the same to treat disorders, such as autoimmune disorders or cancers.

Abstract: Antibodies and antigen-binding fragments thereof that bind to B-cell maturation antigen (BCMA), and methods of using the same, are provided.

Abstract: The invention provides a Saccharomyces cerevisiae strain for producing a human milk lipid substitute. By integrating a heterologous lysophosphatidic acid acyltransferase into Saccharomyces cerevisiae and knocking out its own natural lysophosphatidic acid acyltransferase, the content of palmitic acid (C16:0) at Sn-2 position of triacylglycerol produced by Saccharomyces cerevisiae is increased, to synthesize a human milk lipid substitute. On this basis, a metabolic pathway related gene is knocked out, to further increase the content of human milk lipid substitute in the product. In the present invention, a human milk lipid substitute is de novo synthesized by Saccharomyces cerevisiae for the first time, in which the total fatty acid is 15% or more, and the relative content of C16:0 at Sn-2 position reaches about 60%.

Abstract: The present disclosure relates to multifunctional binding proteins comprising a first and a second antigen binding domains (ABDs) and all or part of an immunoglobulin Fc region or variant thereof, wherein the first ABD binds specifically to human BCMA and the second ABD binds specifically to human NKp46 and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-? receptor. The disclosure also relates to methods for making said binding proteins, compositions thereof, and their uses, including the treatment or prevention of proliferative disorders, including multiple myeloma (MM).

Abstract: Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided. Methods of inhibiting FGFR3 activity and methods of treating FGFR3-mediated diseases and disorders are also provided.

Abstract: Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided. Methods of inhibiting FGFR3 activity and methods of treating FGFR3-mediated diseases and disorders are also provided.

Abstract: Methods and systems are provided to classify or identify a target molecule or its properties from regions of molecular surface of the target molecule. In an implementation, the system identifies patches of the surface, generates a respective latent space ID and a respective real space ID for each of the patches, uses the latent space IDs and the real space IDs to identify at least one candidate item that includes a surface resembling a surface region of the target molecule, wherein the surface region comprises multiple patches in the plurality of surface patches of the target molecule, and uses the at least one candidate item to determine an identification or a classification of the target molecule.

Abstract: A composite image is accessed that comprises a plurality of complex images of samples of a protein-protein complex comprising a first protein and a second protein. The composite image is masked to generate a masked portion and an unmasked portion. A first three-dimensional (3d) shape of the first protein and a second 3d shape of the second protein is accessed. A plurality of docking models are accessed that each define a candidate pose-pair. For each docking model, the first 3d shape, the second 3d shape, and the candidate pose-pair are applied to generate, for the docking model, a corresponding fitment score that describes a goodness-of-fit between the pose-pair and the docking model. One of the docking models is selected as a sensed model for the protein-protein complex based on the fitment scores.

Abstract: Anti-FGFR3 antigen-binding proteins and antigen-binding binding fragments thereof are provided. Methods of inhibiting FGFR3 activity and methods of treating FGFR3-mediated diseases and disorders are also provided.

Abstract: The present invention discloses an improved process for preparing an important intermediate of linagliptin. In particular, disclosed are a process for preparing a compound V which is an important intermediate of linagliptin and has the structure V, and an industrial process of preparing linagliptin having excellent chemical and optical purities, which is an inhibitor of dipeptidyl peptidase-4 (DPP-IV), from the compound V. The process employs a phase-transfer catalyst, is high in yield, easy and simple to handle, environmentally friendly, suitable for industrial mass production, and can be implemented by a “one-pot process”.

Abstract: A method for detecting a direct-current arc fault of a photovoltaic system is provided. The method includes: obtaining operation parameters of a photovoltaic system, and a current noise signal in a direct-current cable of the photovoltaic system, respectively; adjusting, based on the operation parameters, a threshold, where the threshold is used to determine whether the current noise signal has an arc feature; and sending a photovoltaic system direct-current arc fault signal in a case that it is determined, based on the threshold, that the current noise signal has a arc feature, so as to improve precision in the direct-current arc fault detection of the photovoltaic system. A device, a processor, and a system for detecting a direct-current arc fault of a photovoltaic system are also provided.

Abstract: The present invention discloses an improved process for preparing an important intermediate of linagliptin. In particular, disclosed are a process for preparing a compound V which is an important intermediate of linagliptin and has the structure V, and an industrial process of preparing linagliptin having excellent chemical and optical purities, which is an inhibitor of dipeptidyl peptidase-4 (DPP-IV), from the compound V. The process employs a phase-transfer catalyst, is high in yield, easy and simple to handle, environmentally friendly, suitable for industrial mass production, and can be implemented by a “one-pot process”.